Avadel Pharmaceuticals plc (AVDL)

In the past six months, Alkermes plc announced a definitive agreement to acquire Avadel for up to $20.00 per share in cash. Avadel reached a global settlement with Jazz Pharmaceuticals, resolving ongoing litigation concerning LUMRYZ. The hedge fund ASL Strategic Value Fund publicly criticized Avadel's management for allegedly mishandling the LUMRYZ launch. Avadel's stock price surpassed its 200-day moving average in October 2025.

There is no specific information available regarding demand seasonality for Avadel Pharmaceuticals Plc's products or services. The company has reported consistent patient adoption of LUMRYZ and continuous revenue growth, suggesting a steady uptake rather than pronounced seasonal fluctuations.

Avadel Pharmaceuticals Plc is an Irish biopharmaceutical company focused on developing and commercializing sleep disorder medicines. Its flagship product is LUMRYZ, an extended-release oral suspension approved by the FDA as a once-at-bedtime oxybate for narcolepsy. Avadel leverages proprietary polymer-based drug delivery technologies, including Micropump, LiquiTime, and Medusa, for controlled-release formulations.

Avadel Pharmaceuticals Plc is headquartered in Dublin, Ireland, with operations in St. Louis, Missouri, in the United States, and Lyon, France. It sells its pharmaceutical products in the United States and Ireland.

Avadel Pharmaceuticals' brand reputation has been shaped by the FDA approval of LUMRYZ and the settlement of litigation with Jazz Pharmaceuticals. However, the company faced reputational pressure when ASL Strategic Value Fund accused management of mismanaging the LUMRYZ launch. The announced acquisition by Alkermes plc can be seen as a positive validation of Avadel's product and strategy.

Institutional investors hold a significant majority stake in Avadel Pharmaceuticals Plc, reported as 73% or 73.61% of the company. Major institutional owners include Janus Henderson Group Plc, BlackRock, Inc., and Vanguard Group Inc. Insiders also own shares in the company, with Charles Brandes owning the most shares individually.